Celgene Chairman To Retire, Current CEO to Take Role
Celgene Executive Chairman Bob Hugin plans to retire after 19 years of service and will step down from Celgene’s board of directors, effective February 5, 2018. Chief Executive Officer (CEO) Mark Alles has been appointed to the additional role of chairman of the board of directors.
Hugin joined Celgene in 1999 as chief financial officer. He served as president and chief operating officer from 2006 to 2010, and CEO from 2010 until becoming executive chairman in March 2016. Hugin was elected to serve on the board of directors in December 2001 and became chairman in June 2011. Under Hugin’s leadership, Celgene’s portfolio of approved products doubled, and Celgene grew from a company with 2500 employees in 2010 to a company with 7500 employees in 2018, according to Celgene.
CEO and newly appointed Chairman Mark Alles has been with Celgene since 2004. Prior to becoming CEO in 2016, Alles served as president and chief operating officer, and prior to that, as executive vice president and global head of hematology and oncology.